Sugi Predict

Sugi Predict / Compounds / SCHEMBL558157

SCHEMBL558157

SCHEMBL558157

COC(=O)c1cccc(C(=O)OC(C)(C)C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.53
▸ LOXL2 Q9Y4K0 1/20 0.53
▸ SLC7A5 Q01650 2/20 0.52
▸ CYP4F2 P78329 2/20 0.51
▸ CYP4A11 Q02928 2/20 0.51
▸ RAB9A P51151 3/20 0.50
▸ POLB P06746 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ NPC1 O15118 2/20 0.47
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CA7 P43166 1/20 0.47
▸ XDH P47989 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ STAT3 P40763 1/20 0.47
▸ TP53 P04637 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110296 0.92 SLC7A5 (0.58) TSHRLOXL2SLC7A5CYP4F2CYP4A11
Hydrogen Peroxide SCHEMBL27146001 0.90 SLC7A5 (0.60) TSHRLOXL2SLC7A5RAB9AALDH1A1
Water SCHEMBL28897664 0.90 SLC7A5 (0.56) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL28350987 0.90 SLC7A5 (0.56) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL27261815 0.89 SLC7A5 (0.50) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL17747120 0.88 CA1 (0.54) TSHRPOLBALDH1A1CA12CA1
SCHEMBL16719850 0.87 GABRA1 (0.53) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL27468465 0.86 LOXL2 (0.47) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL20023253 0.86 LOXL2 (0.47) TSHRLOXL2SLC7A5CYP4F2CYP4A11
SCHEMBL34953 0.86 TSHR (0.70) TSHRLOXL2SLC7A5CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107964018-A Substituted purin ketones derivant and its medical usage 中国人民解放军军事医学科学院毒物药物研究所 2018-04-27 — — CN claimed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 — — US disclosed
US-20230192629-A1 METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES AMO PHARMA LTD. (US) 2023-06-22 — — US disclosed
CN-111433577-B Temperature detection label and article management device using same 株式会社日立制作所 2021-09-21 — — CN disclosed
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2019-05-23 — — US disclosed
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 — — US disclosed
US-9145354-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2015-09-29 — — US disclosed
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-19 — — US disclosed
EP-2773615-A1 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2014-09-10 — — EP disclosed
EP-2256130-B1 Novel insulin derivatives NOVO NORDISK AS (DK) 2013-09-25 — — EP disclosed
US-8067362-B2 Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents NOVO NORDISK AS (DK) 2011-11-29 — — US disclosed
US-20110034507-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2011-02-10 — — US disclosed
US-20110034507-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2011-02-10 — — US disclosed
EP-2256130-A1 Novel insulin derivatives Novo Nordisk A/S (DK) 2010-12-01 — — EP disclosed
EP-2173174-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-14 — — EP disclosed
WO-2009005998-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2009-01-08 — — WO disclosed
WO-2009005998-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2009-01-08 — — WO disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 — — US disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF MALT1, MYLK2, FKBP1B TSHR 4178/4885LOXL2 3183/4885SLC7A5 2750/4885
US-20080076705-A1 Insulin Derivatives IAPP, INSR, GPR119 TSHR 597/4885LOXL2 4118/4885SLC7A5 75/4885
US-20110034507-A1 FARNESOID X RECEPTOR AGONISTS NR1H4, NR1H3, NR1H2 TSHR 1150/4885LOXL2 3933/4885SLC7A5 2720/4885
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS NR1H4, HAVCR2, NR1H3 TSHR 99/4885LOXL2 3277/4885SLC7A5 341/4885
US-20230192629-A1 METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES FNTB, FNTA, FDPS TSHR 1967/4885LOXL2 4701/4885SLC7A5 1783/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 TSHR 3756/4885LOXL2 365/4885SLC7A5 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.